29 August 2008
Use and overuse of proton pump inhibitors in cirrhotic patients
Norberto C. Chavez-TapiaBCDEF, Felix I. Tellez-AvilaBCDEF, Jorge Garcia-LeivaEF, Miguel Angel ValdovinosACDEMed Sci Monit 2008; 14(9): CR468-472 :: ID: 867964
Abstract
Background
There are several indications for the use of proton pump inhibitors (PPIs) but little evidence to support their use in patients with chronic liver disease. Moreover, the pattern of clinical use is unknown. The aim of the present study was to analyze the use of PPIs in patients with chronic liver disease in an ambulatory setting.
Material and Method
This was a retrospective study in a clinical setting. Clinical variables, severity indexes, and endoscopic findings were assessed. Management of PPIs was classified according to proven indication as: G1, proven indication and a prescription; G2, no proven indication and prescription; G3, proven indication and no prescription; and G4, no proven indication and no prescription. G1+G4 were considered proper use of PPIs. The classification was used to identify variables associated with proper use.
Results
The study included 243 patients (mean age: 55.82+/-12.9 years). The most common etiologies of chronic liver disease were hepatitis C virus infection and chronic alcoholic liver disease. PPIs were indicated in 46.1% patients. Multivariate analysis showed that a MELD score < or =8 points (OR: 2.6, 95% CI: 1.3-5.3), esophageal varices (OR: 0.38, 95% CI: 0.16-0.90), and previous in-hospital use of PPIs (OR: 0.78, 95% CI: 0.6-0.9) were associated with G1+G4.
Conclusions
Clinical use of PPIs in chronic liver disease was inappropriate in nearly one half of all patients. A less severe disease was associated with proper use and previous in-hospital use was associated with inappropriate use. Future research into the clinical use of PPIs in cirrhotic patients is mandatory.
Keywords: Proton Pump Inhibitors - therapeutic use, Liver Cirrhosis - physiopathology, Drug Utilization Review, Child, Blood Chemical Analysis, Analysis of Variance
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952